Biotronik study demonstrates benefits of Pulsar-18 stent

Biotronik has announced new data that demonstrates the effectiveness of its Pulsar-18 stent in treatment of superficial femoral artery disease.

The bare metal self-expanding stent was recently studied in the BIOFLEX PEACE all-comers trial, which evaluated the device's performance among 151 all-comers over a 12-month period.

Interim results indicated that Pulsar-18 is an effective treatment option for superficial femoral artery disease, with a primary patency rate of 75 percent and a freedom from target lesion revascularisation rate of 93.1 percent.

This confirmed the results of previous Pulsar studies and offered further evidence, taken from a real-world setting, that the stent can offer numerous benefits for this patient group.

Dr Alexander Uhl, vice-president of marketing for vascular intervention at Biotronik, said: "This interim data is highly encouraging and we look forward to the full data set from BIOFLEX PEACE in 2017, and eventually the 24-month results."

Pulsar stent has a thin strut design producing a low chronic outward force to help reduce restenosis rates, thereby delivering better outcomes.

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.